BRAINSTORM CELL THERAPEUTICS INC.
BCLINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BCLI. That does not mean none is planned.
Get an email about BCLI's next catalysts
Track BRAINSTORM CELL THERAPEUTICS (BCLI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
NurOwn® (MSC-NTF cells)
Amyotrophic Lateral Sclerosis (ALS)
NurOwn (MSC-NTF cells)
Multiple Sclerosis, Chronic Progressive
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Amyotrophic Lateral Sclerosis
MSC-NTF cells transplantation (IM)
Amyotrophic Lateral Sclerosis
Nurown MSC-NTF cells
Amyotrophic Lateral Sclerosis (ALS)
MSC-NTF cells transplantation (IT)
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NurOwn® (MSC-NTF cells) | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
NurOwn (MSC-NTF cells) | Phase 2 | Multiple Sclerosis, Chronic Progressive | - | - |
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
MSC-NTF cells transplantation (IM) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Nurown MSC-NTF cells | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
MSC-NTF cells transplantation (IT) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Amyotrophic Lateral Sclerosis (ALS)
1 drug in this indication
Multiple Sclerosis, Chronic Progressive
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BRAINSTORM CELL THERAPEUTICS INC.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in BRAINSTORM CELL THERAPEUTICS INC.'s (BCLI) pipeline across Phase 3, Phase 2. Its lead program is NurOwn® (MSC-NTF cells) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRAINSTORM CELL THERAPEUTICS INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BCLI biotech catalysts?→
Add BCLI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRAINSTORM CELL THERAPEUTICS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.